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1Chapter
Clinical Validation of a Whole 
Exome Sequencing Pipeline
Debra O. Prosser, Indu Raja, Kelly Kolkiewicz, 
Antonio Milano and Donald Roy Love
Abstract
Establishing whole exome sequencing (WES) in an accredited clinical diagnostic 
space is challenging. The validation (as opposed to verification) of an approach 
that will lead to clinical reports requires adhering to international guidelines and 
recommendations and developing a robust analytical pipeline that can scale due to 
the increasing clinical demand for comprehensive gene screening. This chapter will 
present a step-wise approach to WES validation that any laboratory can follow. The 
focus will be on highlighting the pivotal technical issues that must be addressed in 
validating WES and the analytical tools and QC metrics that must be considered 
before implementing WES in a clinical environment.
Keywords: whole exome sequencing, next-generation sequencing, validation, 
bioinformatics, diagnostics
1. Introduction
The decision as to which type of genetic test should be implemented by a clinical 
laboratory is largely driven by the type of referrals received by the laboratory and 
the complexity of patients’ clinical phenotypes. In the main, testing has advanced 
from single-gene to multi-gene panels in which next-generation sequencing (NGS) 
has offered the technical means of undertaking this approach at low cost and high 
throughput. However, with the increasing awareness of genetic heterogeneity 
combined with gene discovery, whole exome sequencing (WES) offers laboratories 
a more streamlined approach. By implementing a single wet-work pipeline of 
exome capture coupled with the ability to analyze a virtual gene panel or report on 
the whole exome, laboratories can perform NGS in a more efficient manner.
Since the inception of NGS over a decade ago, multiple recommendations 
and guidelines have been published for NGS [1–3]. Using these guidelines, the 
College of American Pathologists (CAP) and Association for Molecular Pathology 
(AMP) published their Practical Framework for Designing and Implementing 
NGS Tests for Inherited Disorders in 2019 [4], and this is available through the 
CAP website (https://www.cap.org/member-resources/precision-medicine/
next-generation-sequencing-ngs-worksheets).
We adopted this framework to establish a diagnostic NGS service using whole 
exome sequencing as our capture procedure and analyzing virtual gene panels or 
WES for reporting purposes.
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The framework provides guidance and editable worksheets for the five steps 
involved in test establishment and validation.
1. Test design: setup
2. Assay design and optimization
3. Test validation
4. Quality management
5. Bioinformatics and IT
Throughout the validation process, it is essential that the NGS workflow is informed 
by the real-world local environment in which clinical testing will be performed.
2. Test design: setup
In view of the diverse range of referrals made to the authors’ genetics laboratory 
(serving the needs of a 400-bed women and children’s hospital in the Middle East), 
a whole exome capture solution was chosen for library preparation. The principal 
motivation behind this determination was to achieve an efficient workflow that 
would allow appropriate batching coupled with a time-limited turnaround time 
(TAT) for all referrals.
The limited number of staff in the authors’ laboratory demanded a WES work-
flow that could be easily automated, twinned with a data analysis package that 
would allow secure remote access with a strong databasing function. The whole 
exome solution capture by SOPHiA™ Genetics was chosen for library preparation. 
This platform allows for the analysis of WES, clinical exome sequencing (CES) and 
clinical gene panels, together with the identification of single-nucleotide variants 
(SNVs) and copy number variants (CNVs) using SOPHiA™ DDM software.
3. Assay design and optimization
The validation pipeline needs to be grounded from the beginning in terms of the 
requirements of the test, which must take into account the sample types the labora-
tory will receive and the parameters that need to be satisfied (see Table 1).
Routinely, whole blood samples collected in EDTA are received by the authors’ 
laboratory for testing. Therefore, our validation focused only on genomic DNA 
extracted from whole blood using our standard methods. The baseline validation of 
the WES data required the inclusion of two HapMap gDNA samples: the NIST control 
(NA12878) and the commercial control (SG063) supplied by SOPHiA™ Genetics.
The WES capture by SOPHiA™ Genetics was used for library preparation 
following all the steps as set out by the automated WES 32 reaction protocol. For 
instrumentation, our validation was restricted to automated library preparation 
using the PE Sciclone® G3 NGS workstation and sequencing using the Illumina® 
HiSeq4000 platform.
A critical additional consideration was the need for copy number variant calls to 
be made. This required a minimum batch number of eight patients and high cover-
age requirements, which involved restricting the number of samples per Illumina® 
HiSeq4000 lane to one pool of eight patients.
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Importantly, the naming of the sequence files (.bam,. FASTQ, etc.) should 
be considered during the early phase of test design and validation. File conven-
tions that are used for the bioinformatic process may be limited in terms of the 
type of special characters and/or character length. Following recommenda-
tions in the CAP/AMP-Guidelines for Validating Next-Generation Sequencing 
Bioinformatics Pipelines [5], the identity of the sample must be preserved 
throughout all steps of the bioinformatic pipeline. These authors recommend 
the following four unique identifiers that should be applied to the sample 
file name:
i. Unique sample identifier
ii. Unique patient identifier
iii. Unique run identifier
iv. Laboratory location identifier
It is essential that the file naming convention that is decided upon for validation 
adheres to the above recommendations and can be universally implemented for all 
subsequent testing.
4. Test validation
Test validation mandates a need for accuracy, precision and stability. These 
assessments must be made in the context of expected clinical workloads and perfor-
mance. For the authors’ laboratory, the sample batch size was set at 16 samples per 
validation batch and a total of three validation runs performed over differing days 
with differing technologists.
Analytical performance was characterized by the assessment of precision, 
sensitivity and concordance of variant calls against previously validated data.
Test requirements Must 
have
Nice to 
have
WES Y
CES Y
Clinical panels Y
CNV detection Y
Necessary sample throughput per month 16 32
How deeply does each position need to be covered for accurate variant calling 
(if known—otherwise address during test optimization)
>20x >50x
DNA from whole blood collected in EDTA Y
DNA from external/commercial sources (limitations) Y
Required/expected TAT 3 months 2 months
Combine different tests (existing or planned) within a sequencing run Y
WES, whole exome sequencing; CES, clinical exome sequencing; CNV, copy number variant; TAT, turnaround time.
Table 1. 
Test requirements and limitations.
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Inter-run and intra-run data were achieved by replicate analysis of two HapMap 
gDNAs, the NIST sample, NA12878, and the commercial control supplied by 
SOPHiA™ Genetics, SG063, as well as four well-characterized clinical samples previ-
ously reported by accredited laboratories. The remaining samples included a represen-
tative group of the clinical samples received by the authors’ laboratory (see Table 2).
The complete NGS workflow should be included in the validation, from library 
preparation to bioinformatic analysis to report generation, which is highlighted below.
• Sample collection and DNA extraction. Genomic DNA is extracted and purified 
from blood samples using either the Gentra® PureGene® DNA Blood Mini Kit 
or the QIAsymphony® DSP DNA Midi kit (QIAGEN, Hilden, Germany). DNA 
quality is initially assessed by NanoDrop™ spectrophotometry.
Genomic DNA preparation. The initial preparation of gDNA used in NGS 
library preparation is the most critical step in the NGS workflow, and the care 
and time taken here are key to successful library amplification and sequencing.
High-quality gDNA can be by quantified using a Qubit™ fluorometer followed 
by sequential dilution with further quantification to the desired input concen-
tration. It is essential to minimize pipetting gDNA volumes of less than 5 μl for 
dilution. In our study, gDNA is prepared to a working concentration of 40 ng/
μl. After Qubit™ quantification, the integrity of the gDNA can be analyzed 
using an Agilent TapeStation 4200. Samples with a DNA integrity number 
(DIN) of greater than 7.5 can proceed to WES capture.
• Library preparation, targeted capture and sequencing. Whole exome sequenc-
ing was performed according to the SOPHiA™ Whole Exome Solution 32 
Samples User Guide, in combination with the SOPHiA™ Library Preparation 
and Capture User Guide—automation with PerkinElmer Sciclone® G3 NGS 
workstation. Each validation run consists of 16 samples that are divided into 2 
pools of 8 samples each, as shown in the validation grid in Table 3.
The SOPHiA™ WES protocol for library construction subjects genomic DNA 
(200 ng) to enzymatic fragmentation, end repair and A-tailing. All these steps 
occur using a Sciclone® G3 NGS workstation. The adapter-ligated DNA is then 
amplified in a limited way via an eight-cycle PCR protocol.
Post-amplification cleanup of the libraries is carried out using the Sciclone® 
G3 NGS workstation, and libraries are prepared for quantitation with a dilu-
tion factor of 4.
Amplified libraries are analyzed using Qubit™ fluorometer and Agilent 
TapeStation 4200 to assess the quantity and quality of each individual library. 
Library DNA fragments should have a size distribution between 300 and 
700 bp. Genomic DNA that has been fragmented, end repaired, A-tailed and 
adapter-ligated can then be considered library DNA, which is ready for pooling 
and then hybridization and capture. In the case of the SOPHiA™ WES proto-
col, eight samples are pooled (200 ng of each library) per capture.
Prepared pools are hybridized for 4 h followed by post-capture amplification 
and cleanup on the Sciclone® G3 NGS workstation.
Final library quantification is performed for each captured library pool using 
a Qubit™ fluorometer and Agilent TapeStation 4200. Subsequent pools are 
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Sample 
ID
Description Purpose Purpose (detail) Specific variant/s of interest Variant 
type
Measured metric
VAL-1 NA12878 Baseline validation N/A N/A N/A Intra-run variability 
Inter-run variability
VAL-2 SG063 Baseline validation N/A N/A N/A Intra-run variability 
Inter-run variability
VAL-3 Anonymized 
patient specimen
Baseline validation Variant type Ciliopathy gene panel CCDC39:c.2017G > T p.(Glu673*) 
CCDC39: Deletion of exons 14 to 20
SNV CNV Inter-run variability 
Sensitivity
VAL-4 Anonymized 
patient specimen
Baseline validation Variant type 
prevalent in gene
Single-gene analysis CFTR:c.1521_1523delCTT 
p.(Phe508del)
DEL Inter-run variability 
Sensitivity
VAL-5 Anonymized 
patient specimen
Baseline validation Variant type Craniosynostosis gene panel 
CACNA1H:c.4318_4319delinsGC p.(Phe1440Ala)
DELINS Inter-run variability 
Sensitivity
VAL-6 Anonymized 
patient specimen
Baseline validation Variant type 
prevalent in gene
Tuberous sclerosis gene panel TSC2: Deletion of exons 2 
to 16
CNV Inter-run variability 
Sensitivity
VAL-7 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Arrhythmia cardiomyopathy gene panel 
SCN5A:c.4867C > T p.(Arg1623*)
SNV 
(stop)
Sensitivity
VAL-8 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Custom panel of 196 genes 200 genomic co-ordinates SNV DEL/
DUP
Sensitivity
VAL-9 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Paroxysmal Dystonia gene panel Del 16p11.2 
chr16:29,656,684-30,190,568
CNV Sensitivity
VAL-10 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Leukodystrophy gene panel MLC1:c.908_918delinsGCA 
p.(Val303Glyfs*96)
DELINS Sensitivity
VAL-11 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Epilepsy gene panel WWOX: Deletion of exons 1–5 CNV Sensitivity
VAL-12 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Epilepsy gene panel SNV DEL/
DUP
Sensitivity
VAL-13 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Single-gene analysis CFTR: deletion of exons 4–8 CNV Sensitivity
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Sample 
ID
Description Purpose Purpose (detail) Specific variant/s of interest Variant 
type
Measured metric
VAL-14 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Neuropathy gene panel SNV DEL/
DUP
Sensitivity
VAL-15 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Cholestasis gene panel SNV DEL/
DUP
Sensitivity
VAL-16 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Tuberous sclerosis gene panel (2 genes) 
TSC2:c.5238_5255del p.(His1746_Arg1751del)
DEL Sensitivity
VAL-17 Anonymized 
patient specimen
Chromosomal CNV 
validation
Variant type Molecular karyotype referral Dup 22q11.21 
chr22:18,661,724-21,809,099
CNV Sensitivity
VAL-18 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Primary ciliary dyskinesia gene panel DNAH5: Gain of 
exons 1 to 50 DNAH5:c.5503C > T p.(Gln1835*)
SNV CNV Sensitivity
VAL-19 Anonymized 
patient specimen
Gene-specific 
validation 
(pseudogene)
Variant range Inherited cancer gene panel CDKN2A:c.9_32dup 
p.(Ala4_Pro11dup)
SNV DEL Sensitivity
VAL-20 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Custom panel of 196 genes 200 genomic coordinates SNV DEL/
DUP
Blind analysis
VAL-21 Anonymized 
patient specimen
Chromosomal CNV 
validation
Variant type Molecular karyotype referral Duplication at 16p13.11, 
deletion at 12p31 and duplication at Xp21.1
CNV Sensitivity
VAL-22 Anonymized 
patient specimen
Gene-specific 
validation
Variant type 
prevalent in gene
Single-gene analysis DMD: duplication exons 45–62 CNV Sensitivity
VAL-23 Anonymized 
patient specimen
Gene-specific 
validation
Variant type 
prevalent in gene
Dystrophinopathy gene panel DMD: deletion of exons 8–34 CNV Sensitivity
VAL-24 Anonymized 
patient specimen
Gene-specific 
validation
Variant range Custom panel of 196 genes 200 genomic co-ordinates SNV DEL/
DUP
Sensitivity
VAL-25 Anonymized 
patient specimen
Gene-specific 
validation 
(pseudogene)
Pseudogene Custom panel of nine genes SNV DEL/
DUP
Sensitivity
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Sample 
ID
Description Purpose Purpose (detail) Specific variant/s of interest Variant 
type
Measured metric
VAL-26 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Primary Immunodeficiency gene panel 
TBX1:c.1383_1421del p.(Ala464_Ala476del)
DEL Sensitivity
VAL-27 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Dilated cardiomyopathy gene panel 
TTN:c.75984_75985insTACCA p.(Ala25329Tyrfs*32)
INS Sensitivity
VAL-28 Anonymized 
patient specimen
Gene-specific 
validation
Variant type Pediatric cancer gene panel SMARCB1:c.159_160delinsTAT
CTGGAGGCG (p.Leu54Ilefs*20)
DELINS Sensitivity
DEL, deletion; INS, insertion; DUP, duplication; SNV, single-nucleotide variant; CNV, copy number variant.
Table 2. 
Sample list.
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diluted to 20 nM (in a total volume of 20 μl) and subjected to sequencing using 
an Illumina® HiSeq4000 Sequencing platform.
• Sequence analysis: performance metrics. Baseline performance metrics for the 
WES validation study must involve the analysis of well-characterized reference 
samples: the NIST sample (NA12878) and the SOPHiA™ Genetics control SG063. 
The sequence metrics for each sample in the run must be recorded and averages 
established using the reference samples. Samples must meet the sequencing 
metrics shown in Table 4 in order to reach the threshold for clinical reporting.
Analytical sensitivity and specificity must be calculated separately for each 
variant type (SNV, indel, CNV, etc.). Additional runs may be required to meet 
acceptable confidence intervals for less frequent variant types of insertions 
and deletions. For 95% confidence and 95% reliability, 59 variants of each 
type (and insertion/deletion range) should be analyzed [5]. The variant types 
that do not have strong confidence intervals must be listed in the test limita-
tions of the clinical report until such time that the desired confidence levels 
have been achieved.
Selected sequencing metrics Must have Nice to have
Q30 score >80 >85
Total number of reads per sample >70 M 80–100 M
Percentage of mapped reads >80% >85%
Total percentage on-target reads >90% >95%
Coverage 10% quantile (at this depth, 90% target covered) 20x 50x
Table 4. 
Sequencing metrics.
Run 001 Run 002 Run 003
Pool A A VAL-1
NA12878
VAL-4 A VAL-5 VAL-13 A VAL-21 VAL-5
B VAL-3 VAL-10 B VAL-2
SG-063
VAL-15 B VAL-28 VAL-1
NA12878
C VAL-11 VAL-1
NA12878
C VAL-17 VAL-2
SG-063
C VAL-1
NA12878
VAL-24
D VAL-2
SG-063
VAL-12 D VAL-16 VAL-19 D VAL-3 VAL-25
Pool B E VAL-1
NA12878
VAL-6 E VAL-2
SG-063
VAL-20 E VAL-22 VAL-6
F VAL-7 VAL-8 F VAL-6 VAL-3 F VAL-23 VAL-2
SG-063
G VAL-2
SG-063
VAL-9 G VAL-14 VAL-1
NA12878
G VAL-4 VAL-27
H VAL-5 VAL-2
SG-063
H VAL-18 VAL-4 H VAL-1
NA12878
VAL-26
Copy number variant (CNV) samples are indicated in bold.
Table 3. 
Validation grid.
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5. Quality management
The worksheets described by Santani et al. [4] set out very clear guidance for 
all quality aspects that need to be taken into consideration for the test to meet CAP 
requirements [4]. Through a validation study, the majority of a test’s limitations will 
be discovered and can be recorded against the QC parameters. Table 5 summarizes 
quality metrics that need to be addressed.
Section Category Criteria Specific requirement
Note that these may vary 
between tests and laboratories
Pre-analytical 
QC (per 
sample)
Specimen 
quality
Wrong specimen type Whole blood
Wrong type of tube Purple top EDTA tube
Insufficient quantity ≥0.5 ml
Clotting (blood only) No visible clots
Insufficient labelling Labelling contains name, DOB, 
barcode, date of collection
Expired specimen ≤7 days since collection
Expired collection tube Collection tube not expired
DNA quality and 
quantity
OD 260/280 ratio >1.7
Electrophoretic analysis Shows intact high molecular 
weight DNA band
Quantification ≥500 ng
DNA integrity number 
(DIN)
>7.5
Analytical 
QC (per 
instrument 
run)
Instrument run 
QC
Cluster density Not taken into account
Base quality Q30 ≥ 80
Pipeline QC Total reads passing filter >280 M per lane
% reads not assigned to any 
sample
<5%
Control samples Positive control Expected variants found
Analytical QC 
(per sample)
Library 
preparation
Fragment size and 
distribution
>80% of fragments between 300 
and 700 bp
Pooled library 
concentration
>20 nM
Sample 
de-multiplexing
% reads assigned to sample 8–12%
Read alignment % Reads aligned to target >90%
Distribution of coverage >95% within 25–200×
Coverage 10% quantile 
(at this depth 90% target 
covered at x)
>40×
PCR duplicates <20%
Specimen 
identity
Accurate specimen identity, 
file names with 4 points of 
identification
All worksheets and transfers 
during bench work are witness 
checked for accurate specimen 
identification
Data transfer 
Integrity
Data transfer to secure 
analysis platform
Table 5. 
Quality management.
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Considerations Resources Links
Gene selection Clinical association ClinGen https://clinicalgenome.org/curation-activities/gene-disease-validity/
https://search.clinicalgenome.org/kb/gene-validity
GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1116/
Gene analysis Appropriate transcripts LRG
RefSeq
https://www.lrg-sequence.org/
https://www.ncbi.nlm.nih.gov/refseq/rsg/
Pseudogenes Pseudogene
PanelApp – Genes and 
Entities
http://pseudogene.org/
https://panelapp.genomicsengland.co.uk/panels/
entities/?tag=locus-type-pseudogene
Evaluated homopolymeric regions Ivády et al. [6] DOI: 10.1186/s12864-018-4544-x
Mutation spectrum—reported deep intronic and/or promoter 
region variants
PanelApp—Genes and 
Entities
https://panelapp.genomicsengland.co.uk/panels/entities/?
CNV analysis ClinVar https://www.ncbi.nlm.nih.gov/clinvar/
Decipher https://decipher.sanger.ac.uk/
Establish if critical variants are not covered by assay
Virtual panel 
creation
Expert reviewed panels PanelApp https://panelapp.genomicsengland.co.uk/
ClinGen https://www.clinicalgenome.org/data-sharing/clinvar/
Phenotype-driven HPO https://hpo.jax.org/app/
Table 6. 
Considerations for gene selection, analysis and virtual panel creation.
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6. Bioinformatics and IT
To assess accuracy, genetic variants must be compared against publicly available 
reference data obtained from 1000 Genomes Project.
Clinical association, gene validity and mutation spectrum are applied to the cre-
ation of virtual gene panels in order to aid variant interpretation and reporting. The 
considerations associated with constructing virtual gene panels and the analysis of 
variants are shown in Table 6.
7. Conclusions
The decision to implement WES in a clinical diagnostic environment is one 
that must take into account local context, which encompasses clinical complex-
ity, staff resources, equipment resources and bioinformatic expertise. The deci-
sions described here were made based on the above considerations with a view to 
establishing opportunity, the most important of which was to have a WES pipeline 
that could scale over time in terms of patients tested and with the potential to be a 
regional resource.
It should be stressed, however, that a WES pipeline is sandwiched by two criti-
cal elements: first, the need to focus on the quality and accurate quantitation of 
genomic DNA; which dictates the quality of everything that happens downstream, 
and second, to understand that the identification of DNA variants is technically 
demanding but the classification of those variants is not currently a fully auto-
mated process. The former can sometimes be overlooked, while the latter can be a 
daunting exercise. It is perhaps the subject of another book chapter to discuss the 
approaches to variant classification.
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